CS1 to Treat Pulmonary Arterial Hypertension Granted Orphan Drug Status
source: pixabay.com

CS1 to Treat Pulmonary Arterial Hypertension Granted Orphan Drug Status

The FDA recently granted Orphan Drug status to CS1, a drug therapy from Cereno Scientific, according to Pulmonary Hypertension News. CS1 is designed to provide safe and effective treatment for…

Continue Reading CS1 to Treat Pulmonary Arterial Hypertension Granted Orphan Drug Status
FDA Accepts NDA for a Potential Pulmonary Arterial Hypertension Treatment
source: pixabay.com

FDA Accepts NDA for a Potential Pulmonary Arterial Hypertension Treatment

According to a story from globenewswire.com, the biopharmaceutical company Liquidia Technologies, Inc. just announced that the company's New Drug Application (NDA) has been officially accepted by the US Food and…

Continue Reading FDA Accepts NDA for a Potential Pulmonary Arterial Hypertension Treatment
Two Part Treatment Proven Superior for Pulmonary Arterial Hypertension
source: pixabay.com

Two Part Treatment Proven Superior for Pulmonary Arterial Hypertension

According to a story from Pulmonary Hypertension News, the results of a recent phase 3 clinical trial have determined that patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) stand…

Continue Reading Two Part Treatment Proven Superior for Pulmonary Arterial Hypertension
Anticoagulation Beneficial for Idiopathic Pulmonary Arterial Hypertension
source: pixabay.com

Anticoagulation Beneficial for Idiopathic Pulmonary Arterial Hypertension

According to a story from Pulmonary Advisor, the results of a recent analysis led researchers to conclude that systemic anticoagulation therapy can be beneficial for patients with idiopathic pulmonary arterial…

Continue Reading Anticoagulation Beneficial for Idiopathic Pulmonary Arterial Hypertension
The Effects of Race on Pulmonary Arterial Hypertension Outcomes
source: pixabay.com

The Effects of Race on Pulmonary Arterial Hypertension Outcomes

According to a story from consultant360.com, a recent study was conducted in order to determine if racial ancestry had any impacts on outcomes in the rare disease pulmonary arterial hypertension…

Continue Reading The Effects of Race on Pulmonary Arterial Hypertension Outcomes
Identifying Genetic Origins of Pulmonary Arterial Hypertension in Children
source: pixabay.com

Identifying Genetic Origins of Pulmonary Arterial Hypertension in Children

According to a study on the Wiley Online Library, the genetic factors in pediatric cases of pulmonary arterial hypertension (PAH) are distinct from those of adults. In addition, genetics tends…

Continue Reading Identifying Genetic Origins of Pulmonary Arterial Hypertension in Children
Can This Hormone That Regulates Sleep Treat Pulmonary Arterial Hypertension Symptoms?
source: pixabay.com

Can This Hormone That Regulates Sleep Treat Pulmonary Arterial Hypertension Symptoms?

According to a story from Pulmonary Hypertension News, the results of a recent mouse study has produced some remarkable results. The study found that melatonin, a naturally occurring hormone in…

Continue Reading Can This Hormone That Regulates Sleep Treat Pulmonary Arterial Hypertension Symptoms?
Researchers Identify Method to Help Detect Pulmonary Arterial Hypertension in Systemic Sclerosis Patients
source: pixabay.com

Researchers Identify Method to Help Detect Pulmonary Arterial Hypertension in Systemic Sclerosis Patients

According to a story from Pulmonary Hypertension News, a recent study has determined that cardiopulmonary exercise testing can be an effective method to help identify systemic sclerosis patients that are…

Continue Reading Researchers Identify Method to Help Detect Pulmonary Arterial Hypertension in Systemic Sclerosis Patients

Dr. Marc Bonaca Presents Insight Into Future Trends for Cardiovascular Disease and the Need For Teamwork

Dr. Marc Bonaca, a cardiologist with the Brigham and Women's Hospital in Boston, recently gave a presentation at the Las Vegas 2019 VIVA conference on trends in vascular disease. As reported in…

Continue Reading Dr. Marc Bonaca Presents Insight Into Future Trends for Cardiovascular Disease and the Need For Teamwork

Blood-Derived Biomarkers and Right Ventricular Function: Pulmonary Arterial Hypertension and Congenital Heart Disease

According to a posting from clinicaltrials.gov, an observational study will be focused on the identification of biomarkers for pediatric congenital heart disease and pulmonary arterial hypertension. Biomarkers derived from the…

Continue Reading Blood-Derived Biomarkers and Right Ventricular Function: Pulmonary Arterial Hypertension and Congenital Heart Disease
FDA Announces Label Expansion for Treprostinil to treat Pulmonary Arterial Hypertension
jarmoluk / Pixabay

FDA Announces Label Expansion for Treprostinil to treat Pulmonary Arterial Hypertension

According to a story from MDMag, the US Food and Drug Administration (FDA) has recently approved a label expansion for the drug treprostinil (marketed as Orentiram). This update to the…

Continue Reading FDA Announces Label Expansion for Treprostinil to treat Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension and Diet: What You Need to Know

According to a story from Pulmonary Hypertension News, pulmonary arterial hypertension and its variants can ultimately result in a cascade of impacts on other areas of the body, including the…

Continue Reading Pulmonary Arterial Hypertension and Diet: What You Need to Know
Company Earns Breakthrough Device Designation for Pulmonary Arterial Hypertension
Bokskapet / Pixabay

Company Earns Breakthrough Device Designation for Pulmonary Arterial Hypertension

According to a story from Benzinga, the medical device company V-Wave Ltd. has recently announced that a product in development by the company has earned Breakthrough Device designation from the…

Continue Reading Company Earns Breakthrough Device Designation for Pulmonary Arterial Hypertension

An Experimental Treatment for Pulmonary Arterial Hypertension Just Earned Orphan Drug Designation

According to a story from firstworldpharma.com, the biopharmaceutical company Acceleron Pharma, Inc., recently announced that the company's experimental product candidate sotatercept has earned Orphan Drug designation from the US Food…

Continue Reading An Experimental Treatment for Pulmonary Arterial Hypertension Just Earned Orphan Drug Designation
Phase 2a Trial of Experimental Pulmonary Arterial Hypertension Drug Begins
source: pixabay.com

Phase 2a Trial of Experimental Pulmonary Arterial Hypertension Drug Begins

According to a story from BioSpace, the biopharmaceutical company Altavant Sciences has recently announced that the first patient has been dosed in a phase 2a proof of concept trial. This…

Continue Reading Phase 2a Trial of Experimental Pulmonary Arterial Hypertension Drug Begins
Extension Trial Finds That Orenitram Improves Walking Distance in Pulmonary Arterial Hypertension
Fotorech / Pixabay

Extension Trial Finds That Orenitram Improves Walking Distance in Pulmonary Arterial Hypertension

According to a story from Pulmonary Arterial Hypertension News, data from an open label extension trial of the drug Orenitram as a treatment for pulmonary arterial hypertension has demonstrated that…

Continue Reading Extension Trial Finds That Orenitram Improves Walking Distance in Pulmonary Arterial Hypertension
Study Finds Poor Adherence to PDE-5I Drugs Can Have Consequences in Pulmonary Arterial Hypertension
guvo59 / Pixabay

Study Finds Poor Adherence to PDE-5I Drugs Can Have Consequences in Pulmonary Arterial Hypertension

According to a story from Pulmonary Hypertension News, a recent study has found that lapses in treatment adherence can result in serious side effects for pulmonary arterial hypertension (PAH) patients…

Continue Reading Study Finds Poor Adherence to PDE-5I Drugs Can Have Consequences in Pulmonary Arterial Hypertension

Issues with Quality Assurance of Generic Drugs and How We Can Improve the Process

What are Generic Drugs? Generic drugs are any medications "equivalent" to brand name pharmaceuticals. These drugs are much cheaper than the brand name medications and the United States Food and…

Continue Reading Issues with Quality Assurance of Generic Drugs and How We Can Improve the Process
Study Finds Similar Survival Rates in Idiopathic and Disease Associated Pulmonary Arterial Hypertension
1643606 / Pixabay

Study Finds Similar Survival Rates in Idiopathic and Disease Associated Pulmonary Arterial Hypertension

According to a story from Pulmonary Hypertension News, a recent study found that patients with disease-associated pulmonary arterial hypertension had similar rates of survival compared to patients with idiopathic pulmonary…

Continue Reading Study Finds Similar Survival Rates in Idiopathic and Disease Associated Pulmonary Arterial Hypertension

Singer Charity Sunshine Tillemann-Dick Passed Away From Pulmonary Arterial Hypertension at Age 35

According to a story from radio.wpsu.org, soprano singer Charity Sunshine Tillemann-Dick recently passed away at the young age of 35 because of pulmonary arterial hypertension, a rare condition of increased…

Continue Reading Singer Charity Sunshine Tillemann-Dick Passed Away From Pulmonary Arterial Hypertension at Age 35
Development of “Add-on” Therapy for Pulmonary Arterial Hypertension Ends After Poor Trial Showing
Fotorech / Pixabay

Development of “Add-on” Therapy for Pulmonary Arterial Hypertension Ends After Poor Trial Showing

According to a story from Pulmonary Hypertension News, the drug developer United Therapeutics recently issued a statement in which the company announced that it was ceasing the development of esuberaprost…

Continue Reading Development of “Add-on” Therapy for Pulmonary Arterial Hypertension Ends After Poor Trial Showing
Funding Goal Achieved for Pulmonary Arterial Hypertension Clinical Trial
jarmoluk / Pixabay

Funding Goal Achieved for Pulmonary Arterial Hypertension Clinical Trial

According to a story from Euroinvestor, the drug development company Resverlogix Corp. recently announced that it has received the necessary $2.9 million in funding for a Phase 2 clinical trial…

Continue Reading Funding Goal Achieved for Pulmonary Arterial Hypertension Clinical Trial
Close Menu